Advancing Second-Line Therapy in Extensive-Stage Small-Cell Lung Cancer
Small-cell lung cancer (SCLC) remains one of the most aggressive malignancies, characterized by high relapse rates and a dismal prognosis, particularly in the second-line setting, where standard therapies…
